← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Phaos Technology Holdings (Cayman) Limited (POAS) 10-Year Financial Performance & Capital Metrics

POAS • • Industrial / General
HealthcareMedical DevicesDiagnostic & Imaging EquipmentMedical Imaging Systems
AboutPhaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the assembling and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore, Southeast Asia, and South Asia. The company offers Optonano that enables users to view live and still images for construction of high-quality image of larger sample areas; PT-Industrial for use in material study, failure analysis, simple measuring, quality control, inspection, and manufacturing; and PT-Metrology, which provides dimensional measurements with a single key operation. It also provides PT-Biology to create specialized images needed in the biomedical sector; PT-Stereo, a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples; and PT-Zoom that offers three-dimensional magnified view of samples to enhance visualization. In addition, the company offers software. The company serves manufacturing companies comprising printed circuit boards, electronics, precision engineering, injection molding, and QA/QC; biomedical service providers; and research and development institutions. The company was founded in 2017 and is based in Singapore.Show more
  • Revenue $2M +189.3%
  • EBITDA -$2M -26.0%
  • Net Income -$2M -41.5%
  • EPS (Diluted) 0.00 +100.0%
  • Gross Margin 47.68% +170.7%
  • EBITDA Margin -123.56% +56.5%
  • Operating Margin -132.95% +57.6%
  • Net Margin -125.34% +51.1%
  • ROE -80.81%
  • ROIC -
  • Debt/Equity 0.27
  • Interest Coverage -57.49 +29.4%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Share count reduced 100.0% through buybacks

✗Weaknesses

  • ✗Negative free cash flow

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-

EPS CAGR

10Y-
5Y-
3Y-
TTM-

ROCE

10Y Avg-646.74%
5Y Avg-646.74%
3Y Avg-646.74%
Latest-646.74%

Peer Comparison

Medical Imaging Systems
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
IRMDIRadimed Corporation1.3B102.5768.3811.71%26.31%21.54%1.35%0.00
BRKRBruker Corporation7.52B49.4665.0813.56%-0.61%-0.84%1.81%1.24
STESTERIS plc26.33B268.2643.276.24%12.07%9.8%2.95%0.33
FONRFONAR Corporation114.98M18.6415.151.43%7.08%4.62%6.48%0.24
HYPRHyperfine, Inc.100.18M1.22-2.1816.84%-378.17%-149.05%0.01
PACBPacific Biosciences of California, Inc.709.48M2.35-2.20-23.19%-325.8%-13.95%1.33
IRIXIRIDEX Corporation23.21M1.35-2.50-6.17%-10.04%-108.67%2.21
MASS908 Devices Inc.199.79M5.52-2.6018.72%-7.17%-3.03%0.06

Profit & Loss

Apr 2023Apr 2024
Sales/Revenue+650.8K1.88M
Revenue Growth %-1.89%
Cost of Goods Sold+536.17K985.1K
COGS % of Revenue0.82%0.52%
Gross Profit+114.63K897.7K
Gross Margin %0.18%0.48%
Gross Profit Growth %-6.83%
Operating Expenses+2.16M3.4M
OpEx % of Revenue3.31%1.81%
Selling, General & Admin1.59M2.09M
SG&A % of Revenue2.44%1.11%
Research & Development26.96K90.57K
R&D % of Revenue0.04%0.05%
Other Operating Expenses538.74K1.22M
Operating Income+-2.04M-2.5M
Operating Margin %-3.14%-1.33%
Operating Income Growth %--0.23%
EBITDA+-1.85M-2.33M
EBITDA Margin %-2.84%-1.24%
EBITDA Growth %--0.26%
D&A (Non-Cash Add-back)195.64K176.71K
EBIT-1.64M-2.32M
Net Interest Income+-25.06K-43.54K
Interest Income00
Interest Expense25.07K43.54K
Other Income/Expense374.39K143.28K
Pretax Income+-1.67M-2.36M
Pretax Margin %-2.56%-1.25%
Income Tax+00
Effective Tax Rate %1%1%
Net Income+-1.67M-2.36M
Net Margin %-2.56%-1.25%
Net Income Growth %--0.41%
Net Income (Continuing)-1.67M-2.36M
Discontinued Operations00
Minority Interest00
EPS (Diluted)+-0.620.00
EPS Growth %-1%
EPS (Basic)-0.620.00
Diluted Shares Outstanding2.7M0
Basic Shares Outstanding2.7M0
Dividend Payout Ratio--

Balance Sheet

Apr 2023Apr 2024
Total Current Assets+909.3K4.73M
Cash & Short-Term Investments54.1K2.31M
Cash Only54.1K2.31M
Short-Term Investments00
Accounts Receivable567.03K1.94M
Days Sales Outstanding318.02376.78
Inventory151.52K187.58K
Days Inventory Outstanding103.1569.5
Other Current Assets20.04K225.7K
Total Non-Current Assets+473.07K451.45K
Property, Plant & Equipment473.07K451.45K
Fixed Asset Turnover1.38x4.17x
Goodwill00
Intangible Assets00
Long-Term Investments00
Other Non-Current Assets00
Total Assets+1.38M5.18M
Asset Turnover0.47x0.36x
Asset Growth %-2.75%
Total Current Liabilities+3.75M2.05M
Accounts Payable91.09K293.91K
Days Payables Outstanding62.01108.9
Short-Term Debt143.35K440.45K
Deferred Revenue (Current)00
Other Current Liabilities32K32K
Current Ratio0.24x2.31x
Quick Ratio0.20x2.22x
Cash Conversion Cycle359.16337.39
Total Non-Current Liabilities+651.68K219.34K
Long-Term Debt574.56K133.98K
Capital Lease Obligations77.12K85.36K
Deferred Tax Liabilities00
Other Non-Current Liabilities00
Total Liabilities4.4M2.26M
Total Debt+885.35K792.58K
Net Debt831.26K-1.52M
Debt / Equity-0.27x
Debt / EBITDA--
Net Debt / EBITDA--
Interest Coverage-81.47x-57.49x
Total Equity+-3.02M2.92M
Equity Growth %-1.97%
Book Value per Share-1.12-
Total Shareholders' Equity-3.02M2.92M
Common Stock2.65K3.49K
Retained Earnings-4.67M-7.03M
Treasury Stock00
Accumulated OCI00
Minority Interest00

Cash Flow

Apr 2023Apr 2024
Cash from Operations+-1.79M-1.61M
Operating CF Margin %-2.75%-0.85%
Operating CF Growth %-0.1%
Net Income-1.67M-2.36M
Depreciation & Amortization195.64K176.71K
Stock-Based Compensation00
Deferred Taxes00
Other Non-Cash Items81.28K153.71K
Working Capital Changes-397.62K419.95K
Change in Receivables-477.78K154.44K
Change in Inventory116.53K-36.06K
Change in Payables-33.49K202.81K
Cash from Investing+-187.89K-1.65M
Capital Expenditures-217.64K-121.32K
CapEx % of Revenue0.33%0.06%
Acquisitions--
Investments--
Other Investing29.75K-1.53M
Cash from Financing+1.91M5.52M
Debt Issued (Net)--
Equity Issued (Net)--
Dividends Paid00
Share Repurchases--
Other Financing0-224.69K
Net Change in Cash--
Free Cash Flow+-2.01M-1.73M
FCF Margin %-3.08%-0.92%
FCF Growth %-0.14%
FCF per Share-0.74-
FCF Conversion (FCF/Net Income)1.07x0.68x
Interest Paid25.07K43.54K
Taxes Paid00

Key Ratios

Metric20222023
Return on Equity (ROE)--80.81%
Gross Margin17.61%47.68%
Net Margin-256.27%-125.34%
Debt / Equity-0.27x
Interest Coverage-81.47x-57.49x
FCF Conversion1.07x0.68x
Revenue Growth-189.31%

Frequently Asked Questions

Growth & Financials

Phaos Technology Holdings (Cayman) Limited (POAS) reported $1.9M in revenue for fiscal year 2023. This represents a 189% increase from $0.7M in 2022.

Phaos Technology Holdings (Cayman) Limited (POAS) grew revenue by 189.3% over the past year. This is strong growth.

Phaos Technology Holdings (Cayman) Limited (POAS) reported a net loss of $2.4M for fiscal year 2023.

Dividend & Returns

Phaos Technology Holdings (Cayman) Limited (POAS) has a return on equity (ROE) of -80.8%. Negative ROE indicates the company is unprofitable.

Phaos Technology Holdings (Cayman) Limited (POAS) had negative free cash flow of $1.7M in fiscal year 2023, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.